FLASCO OncoPod
The FLASCO OncoPod is a podcast series that brings you engaging interviews and conversations with oncology champions and thought leaders. Each episode explores important topics in cancer care, from the latest clinical advancements to FLASCO events and initiatives. Whether it’s discussing groundbreaking research, policy updates, or sharing personal stories from members, the OncoPod keeps oncology professionals informed and connected. It’s your go-to source for staying up-to-date on FLASCO’s efforts to support and strengthen the oncology community across Florida.
The Nuance in mTNBC | Part 2: The Patient the Trial Did Not Enroll
How should clinicians approach metastatic triple-negative breast cancer (mTNBC) when a patient's treatment history does not align with the populations studied in clinical trials? In this episode of The Nuance in mTNBC, Dr. Edgardo Santos and Dr. Victoria Rizk explore the challenges of managing patients who experience recurrence following neoadjuvant immunotherapy and chemotherapy.
Through case-based discussion and insights from a FLASCO clinician survey, faculty examine the significance of treatment-free intervals, prior immunotherapy exposure, germline BRCA mutations, and the evolving first-line treatment landscape. The conversation also addresses the limitations of available clinical evidence, considerations for immunotherapy rechallenge, and...
The Nuance in mTNBC | Part 1: Where the Answers Split
Treatment decisions in metastatic triple-negative breast cancer (mTNBC) are becoming increasingly complex as new therapeutic options reshape the first-line landscape. In this episode of The Nuance in mTNBC, Dr. Edgardo Santos and Dr. Victoria Rizk examine the clinical decisions surrounding PD-L1 expression, germline BRCA mutations, and the evolving role of antibody-drug conjugates (ADCs). Drawing on insights from a FLASCO clinician survey, the discussion explores biomarker testing, treatment selection while results are pending, and the implications of recent first-line sacituzumab govitecan approvals.
Faculty review findings from the ASCENT-03 and ASCENT-04 trials, address areas of clinical uncertainty...
Drew Piers on Advocacy, Storytelling & Shaping the Future of Cancer Care
In this episode of the FLASCO OncoPod, Drew Piers, President of Sachs Media, explores the powerful role advocacy, storytelling, and strategic communications play in advancing cancer care beyond the clinic. Drawing on years of experience working alongside healthcare organizations and oncology professionals, Drew discusses how trusted clinician voices can influence public policy, improve patient access to care, and strengthen public confidence in the healthcare system.
Listeners will gain practical insights into communicating complex healthcare issues with clarity, combining patient stories with evidence-based data, and engaging policymakers in meaningful ways that drive positive change. Whether through community outreach...
The Evolving Management of Hepatocellular Carcinoma: Prevention, Multidisciplinary Care, and Emerging Therapies
Hepatocellular carcinoma (HCC) continues to present unique challenges for oncology teams, requiring coordinated multidisciplinary care and an evolving understanding of both liver disease and cancer management. In this episode of the FLASCO OncoPod, Dr. Beau Bosko Toskich, MD, FSIR, Professor of Radiology, Medical Oncology, and Radiation Oncology and Director of Interventional Oncology at Mayo Clinic Comprehensive Cancer Center, provides a comprehensive overview of the modern HCC treatment landscape.
Dr. Toskich discusses the changing epidemiology of hepatocellular carcinoma, emphasizing the growing impact of metabolic-associated liver disease, the importance of early detection and surveillance, and opportunities for disease prevention...
The Evolving Role of Community Oncology: Delivering Academic-Level Cancer Care Close to Home
In this episode of the FLASCO OncoPod, Dr. McDonough moderates a discussion with Dr. Wenk, Dr. Glick, and Dr. Patel, of Florida Cancer Specialists & Research Institute on the evolving role of community oncology and how today's practices are delivering academic-level cancer care closer to home.
Together, they explore how community oncology has transformed over the past decade, highlighting advances in precision medicine, immunotherapy, clinical research, and innovative care models. The conversation examines how large practice networks maintain consistent, high-quality care while expanding access to cutting-edge therapies and clinical trials for patients across diverse communities.
From...
Part 4, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.
In part 4, the panel examines the real-world barriers that...
Part 3, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.
The panel discusses how expanding biomarker indications are changing...
Part 2, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.
In part 2, the panel explores why routine...
Part 1, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.
The conversation highlights how IHC is shaping...
CLL Treatment Evolution: Rethinking Monotherapy vs Combination Strategies in the Era of Next-Generation BTK Inhibitors
The treatment landscape for chronic lymphocytic leukemia (CLL) has transformed dramatically over the past decade, creating new opportunities and new questions for clinicians managing this increasingly complex disease. In this episode of the FLASCO OncoPod, FLASCO President Edgardo Santos, MD, FACP, FASCO, sits down with renowned CLL expert Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center to discuss how advances in targeted therapies are reshaping treatment decisions across the CLL continuum.
Together, they explore the evolution of CLL care from chemoimmunotherapy to modern treatment approaches centered around BTK inhibitors, BCL2 inhibitors, and anti-CD20 monoclonal antibodies. The conversation...
What's New in Endometrial Cancer: Key Takeaways From SGO 2026
Join Scott E. Jordan, MD, FACOG, gynecologic oncologist at Broward Health, as he breaks down the most important endometrial cancer updates presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting.
In this episode, Dr. Jordan reviews promising new therapies, including emerging antibody-drug conjugates and novel hormonal treatment combinations, highlights exciting clinical trial results, and discusses long-term follow-up data from the practice-changing RUBY trial.
From breakthrough research to upcoming Phase III studies that may shape the future standard of care, this conversation provides oncology professionals with key insights into the rapidly evolving treatment landscape for...
ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon & Dr. Jorge Garcia
What does it take to successfully navigate the business of oncology while continuing to deliver exceptional patient care?
In this episode of the FLASCO OncoPod, Dr. Robin Zon joins Dr. Jorge Garcia for a thoughtful conversation about leadership, advocacy, and the launch of ASCO Edge, a new educational resource designed to help oncology professionals better understand the operational and business side of cancer care.
Dr. Zon reflects on her professional journey from community oncology practice to serving as President of ASCO, sharing how early experiences shaped her passion for empowering clinicians with the tools needed...
"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 3: Genetics, Duration of Therapy, and Real-World Pearls
In this final episode of the FLASCO OncoPod series, Drs. Jaglal, Fu, and Shahzad shift focus to the long-term management of atypical hemolytic uremic syndrome (aHUS) in oncology patients.
Building on the diagnostic and acute management discussions from earlier segments, the panel explores key considerations that guide care beyond the initial presentation. Topics include the role of genetic and complement testing, how to interpret mutation findings, and the factors that influence decisions around the duration of complement inhibition therapy.
Through real-world insights, the discussion highlights the complexity of identifying underlying triggers, including drug exposure and...
"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 2: Acute Management: TTP vs aHUS and Treatment Decisions
In this episode of the FLASCO OncoPod, Drs. Jaglal, Fu, and Shahzad explore the real-world challenges of managing suspected thrombotic microangiopathy (TMA) in oncology patients.
Building on a complex multiple myeloma case introduced in Part 1, this segment focuses on acute decision-making in the hospital setting. The discussion highlights how to differentiate thrombotic thrombocytopenic purpura (TTP) from atypical hemolytic uremic syndrome (aHUS), when to initiate plasma exchange, and how clinicians approach complement inhibition in time-sensitive, high-stakes scenarios.
Through expert insights and practical considerations, the panel walks through key diagnostic clues including peripheral smear findings, LDH elevation...
"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 1: When to Suspect aHUS in Oncology Patients
Atypical hemolytic uremic syndrome (aHUS) in patients with malignancy or undergoing cancer-directed therapy is likely under-recognized, yet early identification can have a profound impact on patient outcomes.
In this FLASCO OncoPod roundtable, Drs. Jaglal, Fu, and Shahzad examine the clinical realities of drug-induced and malignancy-associated aHUS, emphasizing the importance of maintaining a high index of suspicion in complex oncology cases. Through expert insight and real-world experience, they explore how subtle changes in laboratory values and clinical presentation can signal a more serious underlying process.
In this first segment, the discussion centers on when to suspect...
Advancing Care in GI and Biliary Tract Cancers Series Episode 4: GEA Disease State and Patient Management; Importance of the MDT
Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Noman Ashraf, MD, of Tampa General Hospital Cancer Institute for the final installment of the Advancing Care in GI and Biliary Tract Cancers podcast series. This episode focuses on gastroesophageal adenocarcinoma (GEA), exploring the disease state, patient management strategies, and the critical role of the multidisciplinary team (MDT) in delivering comprehensive, high-quality care.
Gastroesophageal adenocarcinoma represents a complex and evolving disease spectrum, encompassing malignancies of the esophagus, gastroesophageal junction, and stomach. With rising incidence rates, particularly in Western populations, clinicians are increasingly faced wi...
Advancing Care in GI and Biliary Tract Cancers Series Episode 3: HER2 Agents in GI Cancers - Understanding Mechanisms of Action
Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Noman Ashraf of Tampa General Hospital Cancer Institute and Dr. Umair Majeed of Mayo Clinic in Jacksonville for the third installment of the Advancing Care in GI and Biliary Tract Cancers podcast series. This episode explores HER2-targeted agents in GI malignancies, with a focus on understanding their distinct mechanisms of action and how these differences influence treatment selection.
HER2 alterations are increasingly recognized across biliary tract, gastric, and colorectal cancers, with a growing number of targeted therapies available. As treatment options expand, un...
Advancing Care in GI and Biliary Tract Cancers Series Episode 2: HER2 Testing in BTC and GEA
Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Paresh Patel and Dr. Masoumeh Ghayouri for the second installment of the Advancing Care in GI and Biliary Tract Cancers podcast series. This episode focuses on HER2 testing in biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA), two GI malignancies where HER2 overexpression is increasingly recognized as an important biomarker for targeted therapy.
HER2 has long been a key therapeutic target in breast cancer, but research now shows that HER2 overexpression occurs in up to 30 percent of biliary tract cancers and approximately 20 percent of...
Advancing Care in GI and Biliary Tract Cancers Series Episode 1: BTC Disease State and Patient Management; Importance of the MDT
Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals and GI Oncologist Dr. Umair Majeed of Mayo Clinic in Jacksonville for the first installment of the Advancing Care in GI and Biliary Tract Cancers podcast series, focused on biliary tract cancers.
The first in the series, this episode provides a comprehensive overview of biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer, highlighting their rarity, evolving epidemiology, and complex biology. Dr. Majeed reviews key risk factors such as chronic liver inflammation, primary sclerosing cholangitis, viral hepatitis, gallstones, and metabolic-associated liver disease, emphasizing th...
Why First-Line Matters: Survival, Sequencing, and Support in EGFR-Mutated Lung Cancer
Join Dr. Edgardo Santos and Dr. Luis Raez for a practical discussion on first-line decision-making in EGFR-mutated lung cancer and how early treatment choices shape survival, sequencing, and patient experience.
This episode explores why first-line therapy represents a critical window for long-term benefit, including the reality that many patients never reach later lines of treatment and the importance of early disease control. The speakers review guideline-supported first-line strategies, discuss how clinicians interpret survival and durability data, and examine the role of CNS disease as a key factor in treatment selection.
The conversation also addresses real-world...
HER2 Testing in BTC and GEA
Join Dr. Paresh Patel and Dr. Masoumeh Ghayouri for a crucial conversation on the complexities of HER2 testing in Gastrointestinal (GI) cancers, including Gastroesophageal Adenocarcinoma (GEA) and Biliary Tract Cancer (BTC).
HER2 status is essential for accessing targeted treatments, but its interpretation in GI cancers is unique and challenging. This episode dives into:
GI vs. Breast Guidelines: Understanding the critical differences in interpreting HER2 Immunohistochemistry (IHC) results, including scoring criteria, membrane staining requirements, and tissue sampling specifics (e.g., cohesive cell clusters in biopsies).Testing Rationale and Methods: Why first-line HER2 testing is now standard for...HER2 Testing in BTC and GEA - Dr. Paresh Patel and Dr. Masoumeh Ghayouri
Join Dr. Paresh Patel and Dr. Masoumeh Ghayouri for a crucial conversation on the complexities of HER2 testing in Gastrointestinal (GI) cancers, including Gastroesophageal Adenocarcinoma (GEA) and Biliary Tract Cancer (BTC).
HER2 status is essential for accessing targeted treatments, but its interpretation in GI cancers is unique and challenging. This episode dives into:
GI vs. Breast Guidelines: Understanding the critical differences in interpreting HER2 Immunohistochemistry (IHC) results, including scoring criteria, membrane staining requirements, and tissue sampling specifics (e.g., cohesive cell clusters in biopsies).Testing Rationale and Methods: Why first-line HER2 testing is now standard for...Beyond the Infusion Chair — Care Team Realities in mCRC
Join moderator Dr. Tiago Bianchi and an expert multidisciplinary panel, including Zilipah Cruz, MSN-RN, ONN-CG, Vanessa Sepulveda-Dominguez, RN, BSN, and Charlotte Martin, PharmD, for a deep dive into the essential non-clinical aspects of metastatic colorectal cancer (mCRC) care.
This episode explores the critical role of the entire oncology team in addressing the Social Determinants of Health (SDOH) and supporting patient survivorship.
Key Challenges & Team Coordination: The panel will discuss the reality of holistic patient support, drawing on survey findings:
SDOH Screening Gaps: While 68% of clinicians report screening for SDOH, most are not using standardized...The mCRC Journey Treatment Sequencing and Real-World Decisions
The mCRC Journey: Treatment Sequencing and Real-World Decisions (Epi. 2)
Join medical oncologists Dr. Tiago Bianchi and Dr. Raji Shameem for Episode 2 of our "Voices in Colorectal Cancer" Series as they navigate the complex, guideline-based, and real-world treatment landscape for metastatic colorectal cancer (mCRC).
This episode delves into current practice, informed by key insights from a recent FLASCO survey:
Molecular Profiling: The doctors confirm molecular profiling is widely adopted (86% of respondents test patients >90% of the time). However, they discuss persistent gaps related to insurance barriers and challenges with specimen quality.Sequencing Strategies: Explore...Younger, Later, Sicker — Changing Faces of Colorectal Cancer
In this first episode of the "Voices in Colorectal Cancer" Series, medical oncologists Dr. Tiago Bianchi and Dr. Raji Shameem confront the dramatic shift in colorectal cancer (CRC) presentation, drawing on urgent, real-world data from a recent FLASCO survey.
The Troubling Trend:
Younger: 91% of clinicians report seeing more CRC cases in patients under age 50, mirroring incidence spikes in Florida and across the US.Later: More than half of all cases are presenting as late-stage at diagnosis—a major gap in current cancer care that severely impacts survival.Sicker: This late presentation means younger patients face more ag...The Missing Treatment Layer: Daily Support That Improves Treatment Tolerance and Completion
In this new OncoPod episode, Dr. Christopher R. Cogle (University of Florida) and Dr. Neil M. Iyengar (Winship Cancer Institute at Emory University) discuss an often-overlooked gap in oncology care - the absence of a structured, non-pharmaceutical treatment layer to help patients stay on therapy and recover stronger.
Drawing on findings from the CHALLENGE trial (NEJM, 2025) and their clinical experience, the experts outline how daily lifestyle interventions in exercise, nutrition, and stress management can improve treatment tolerance, adherence, and even survival. They also explore why these evidence-based approaches have yet to become standard practice and how platforms...
Inside ESR1: How Mutation Testing Shapes Breast Cancer Care
In this episode, FLASCO leaders Maen Hussein, MD, and Wassim McHayleh, MD join the discussion to explore the evolving role of ESR1 mutation testing in metastatic breast cancer. They highlight how these mutations, both acquired and intrinsic, shape treatment decisions and influence patient outcomes. Drawing from real-world data and insights from FLASCO’s statewide survey, the conversation offers practical perspectives on current testing practices, clinical implications, and opportunities to improve personalized care for patients with hormone receptor–positive breast cancer.
This content has been created independently and solely by FLASCO. FLASCO would like to recognize our...
From Paper to Practice: FLASCO’s Consensus Paper on Bispecifics Released
In this episode, Dr. Ariel Perez Perez and Dr. Jose Sandoval-Sus, two of the coauthors of the FLASCO Consensus on Operationalizing Bispecifics for Lymphoma in the Community Setting discuss the core findings and practical recommendations outlined in their paper, highlighting how bispecifics can be safely and effectively delivered in the community setting. They share their perspectives on why this work matters for patient access, safety, and reflect on the importance of multidisciplinary collaboration to expand the use of these therapies beyond academic centers. Listeners are encouraged to engage with the full consensus paper to explore detailed management strategies, operational...
Insights & Understanding of PNH
In this episode, Dr. Michael Jaglal, Dr. Maen Hussein, and Dr. Jorge Garcia come together to discuss paroxysmal nocturnal hemoglobinuria (PNH), a rare but serious hematologic condition. From clinical presentation and diagnostic challenges, to therapy, this expert panel shares real-world insights and strategies to improve patient outcomes.
This content has been created independently and solely by FLASCO. FLASCO would like to recognize our Elite Sponsor, Alexion.
Advances in MDS
Join Dr. Rami Komrokji of Moffitt Cancer Center as he shares expert insights on current trends and considerations in the management of Myelodysplastic Syndromes (MDS).
New Immunotherapy Options for GE Cancers
Tune in as Dr. Tiago Biachi, MD, from Moffitt Cancer Center, explores the latest advancements in immunotherapy for gastroesophageal cancer. In this episode, he breaks down key clinical trial data, examines emerging treatment strategies, and discusses the evolving role of immunotherapy in improving patient outcomes. Don’t miss this expert insight into the future of cancer care!
Updates in IDHm Gliomas - Part II
Tune in for Part 2 of Updates in IDHm Gliomas with FLASCO Neuro-Oncology Captain, Ashley Ghiaseddin, MD, FAAN. This informative podcast covers current and emerging treatments, the evolving role of IDH inhibitors, and the key challenges in treatment, including resistance and tumor heterogeneity. Whether you’re a clinician, researcher, or oncology professional, this FLASCO OncoPod provides valuable insights to enhance patient care and clinical strategies. Listen now to stay at the forefront of glioma treatment advancements!
Updates in IDHm Gliomas - Part I
Join FLASCO for Part I of Updates in IDHm Gliomas with FLASCO Neuro-Oncology Captain, Ashley Ghiaseddin, MD, FAAN. This informative podcast covers current and emerging treatments, the evolving role of IDH inhibitors, and the key challenges in treatment, including resistance and tumor heterogeneity. Whether you’re a clinician, researcher, or oncology professional, this FLASCO OncoPod provides valuable insights to enhance patient care and clinical strategies. Listen now to stay at the forefront of glioma treatment advancements!
Minimal Residual Disease (MRD) Testing
In this installment of the FLASCO OncoPod, we explore the critical role of Minimal Residual Disease (MRD) testing in advancing cancer care with Dr. Ivan Borrello, a distinguished oncologist from Tampa General Hospital.
Dr. Borrello dives into the science behind MRD testing, its applications in hematologic malignancies, and how it informs treatment decisions and long-term patient outcomes. Gain expert insights on the latest advancements in MRD technology and its impact on precision medicine in oncology.
Join us for an enlightening conversation designed for oncology professionals dedicated to staying at the forefront of cancer diagnostics and...
Updates in Lung Cancer
In this episode of the FLASCO OncoPod, we are joined by renowned oncologist Dr. Edgardo Santos, MD, FACP, FCCP, FASCO, from The Oncology Institute of Hope and Innovation (TOI) to discuss the latest updates in lung cancer care.
Dr. Santos shares insights into groundbreaking research, advancements in treatment protocols, and the evolving landscape of lung cancer management. From targeted therapies to immunotherapy breakthroughs, this episode provides a comprehensive look at the innovations improving outcomes for patients.
Don’t miss this engaging discussion designed to inform and inspire oncology professionals across Florida and beyond. Tune in fo...
Management and Treatment of Polycythemia Vera (PV)
In this episode of the FLASCO OncoPod, we delve into the Management and Treatment of Polycythemia Vera (PV) with expert insights from Dr. Andrew Kuykendall, a leading hematologist from Moffitt Cancer Center.
Join us as Dr. Kuykendall explores the latest advancements in PV care, including symptom management, therapeutic strategies, and emerging research that is shaping the future of treatment. Whether you're a clinical oncologist, a healthcare professional, or simply interested in hematologic cancers, this episode provides valuable knowledge and practical takeaways.
Welcome to the FLASCO OncoPod with Dr. Maen Hussein
Introducing the first-ever FLASCO OncoPod! Join FLASCO President, Dr. Maen Hussein, as he dives into the critical role state oncology societies play in advancing cancer care. In this inaugural episode, Dr. Hussein discusses the importance of becoming an active member of your state society, sharing how FLASCO stands as a dedicated supporter and advocate for oncology professionals across Florida. From educational programs to networking opportunities and legislative advocacy, learn how FLASCO continues to empower oncologists, pharmacists, nurses, and allied professionals, helping them navigate the ever-evolving landscape of cancer care. Tune in to be inspired and get involved!
